Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
HOME > LATEST
LATEST
-
REGULATORY Japan Panel Clears Izervay, Nexletol for Approval; Eylea Biosimilars Edge Ahead Too
September 1, 2025
-
REGULATORY METI Proposes “Bold Investment” Tax Breaks in FY2026 Request
September 1, 2025
-
REGULATORY Japan Panel Green Lights Nonprescription Switch of Morning-After Pill
September 1, 2025
-
REGULATORY MHLW Orders Label Revision for Elevidys to Add Acute Hepatic Failure
September 1, 2025
-
BUSINESS Specialist Highlights Lfynua’s Potential for Refractory Chronic Cough
September 1, 2025
-
BUSINESS Medipal, JCR Expand Tie-Up to GM2 Gangliosidosis Drug JR-479
September 1, 2025
-
ORGANIZATION Information Provisioning on Solo Channels Is Duty of Both Makers and Wholesalers: JPMA Distribution Chief
September 1, 2025
-
REGULATORY Japan Doles Out Orphan Tags to Ultragenyx’s GTX-102 and Lots More
September 1, 2025
-
BUSINESS NEC Touts AI as Core of Personalized Cancer Vaccine Development
September 1, 2025
-
REGULATORY Japan Expects COVID Vaccine Supply of 9 Million Doses in 2025-26
September 1, 2025
-
BUSINESS Meiji Bags Japan Approval for 2-Dose COVID Vaccine Vial
September 1, 2025
-
BUSINESS Mitsubishi Tanabe Taps Ex-Pfizer Japan Chief as CEO, Ex-Takeda CFO as Chairman
August 29, 2025
-
BUSINESS Resilire Seeks to Double Pharma Clients for Supply Chain Visualization Platform
August 29, 2025
-
REGULATORY Japan Govt to Spearhead Development of Ultra-Orphan and Infectious Disease Drugs: FY2026 MHLW Budget Request
August 29, 2025
-
BUSINESS Novo Hooks Up with Hirosaki City on Obesity Program for Young Adults
August 29, 2025
-
REGULATORY Japan Moves Toward OTC Morning-After Pill Sales Without Age Limit or Parental Consent
August 29, 2025
-
ORGANIZATION Indicators Needed to Frame Pharma as Growth Market in Japan, Says JPMA Policy Chief
August 29, 2025
-
BUSINESS New PIII Breast Cancer Trial Kicks Off for Daiichi’s HER3 ADC
August 29, 2025
-
BUSINESS Sanofi Files for Subcutaneous Formulation of Sarclisa in Japan
August 29, 2025
-
REGULATORY Diagnostics Industry Urges Mechanism to Reflect Rising Costs in Reimbursement
August 29, 2025
ページ
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…